New Prognostic and Predictive Markers in Cancer Progression
Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient’s outcome and cancer recurrence probability after initial interventions suc...
Kaydedildi:
| Materyal Türü: | Online |
|---|---|
| Dil: | İngilizce |
| Baskı/Yayın Bilgisi: |
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| Konular: | |
| Online Erişim: | ONIX_20210501_9783039439775_119 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|
| _version_ | 1863745007325806592 |
|---|---|
| collection | Directory of Open Access Books |
| description | Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient’s outcome and cancer recurrence probability after initial interventions such as surgery or drug treatments and, hence, to select follow-up and further treatment strategies. On the other hand, predictive markers are increasingly being used to evaluate the probability of benefit from clinical intervention(s), driving personalized medicine. Evolving technologies and the increasing availability of “multiomics” data are leading to the selection of numerous potential biomarkers, based on DNA, RNA, miRNA, protein, and metabolic alterations within cancer cells or tumor microenvironment, that may be combined with clinical and pathological data to greatly improve the prediction of both cancer progression and therapeutic treatment responses. However, in recent years, few biomarkers have progressed from discovery to become validated tools to be used in clinical practice. This Special Issue comprises eight review articles and five original studies on novel potential prognostic and predictive markers for different cancer types. |
| format | Online |
| id | doab-20.500.12854ir-68373 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-683732024-03-31T13:09:58Z New Prognostic and Predictive Markers in Cancer Progression Costantini, Susan Budillon, Alfredo MSI2 OSCC oral cancer musashi 2 prognosis N-cadherin EMT breast cancer new metastasis eribulin blood biomarker bladder cancer immune checkpoint inhibitor CD8+ T effector cells microRNA biomarkers head and neck cancer laryngeal cancer prediction metastasis lifestyle habit chemo-/radio resistance therapeutic target AKT AR castration-resistant prostate cancer (CRPC) MAPK mTOR PI3K prostate cancer therapeutic resistance WNT miRNA melanoma melanoma resistance to MAPK/MEK inhibitors resistance to immune checkpoint inhibitors TNBC BRCA1/2 HRR PDL1 TILs PI3KCA PTEN CTCs CSC pancreatic cancer K-RAS oncogene oncogene dependency targeted therapies genomic mutations transcriptomics metabolomics selenoproteins cancer HUB nodes major histocompatibility complex (MHC) human leukocyte antigen (HLA) antigen processing machinery (APM) molecules carcinogenesis tumor predisposition cancer immunotherapy pheochromocytoma paraganglioma head and neck neoplasms head and neck tumors genetic syndromes mutations hyperglycemia cardioncology nivolumab cytokines cardiotoxicity acetyltransferase cancer prognosis NAA10 n/a thema EDItEUR::M Medicine and Nursing Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient’s outcome and cancer recurrence probability after initial interventions such as surgery or drug treatments and, hence, to select follow-up and further treatment strategies. On the other hand, predictive markers are increasingly being used to evaluate the probability of benefit from clinical intervention(s), driving personalized medicine. Evolving technologies and the increasing availability of “multiomics” data are leading to the selection of numerous potential biomarkers, based on DNA, RNA, miRNA, protein, and metabolic alterations within cancer cells or tumor microenvironment, that may be combined with clinical and pathological data to greatly improve the prediction of both cancer progression and therapeutic treatment responses. However, in recent years, few biomarkers have progressed from discovery to become validated tools to be used in clinical practice. This Special Issue comprises eight review articles and five original studies on novel potential prognostic and predictive markers for different cancer types. 2021-05-01T15:08:23Z 2021-05-01T15:08:23Z 2021 book ONIX_20210501_9783039439775_119 9783039439775 9783039439782 https://directory.doabooks.org/handle/20.500.12854/68373 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/3386 https://mdpi.com/books/pdfview/book/3386 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-03943-978-2 10.3390/books978-3-03943-978-2 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783039439775 9783039439782 294 Basel, Switzerland open access |
| spellingShingle | MSI2 OSCC oral cancer musashi 2 prognosis N-cadherin EMT breast cancer new metastasis eribulin blood biomarker bladder cancer immune checkpoint inhibitor CD8+ T effector cells microRNA biomarkers head and neck cancer laryngeal cancer prediction metastasis lifestyle habit chemo-/radio resistance therapeutic target AKT AR castration-resistant prostate cancer (CRPC) MAPK mTOR PI3K prostate cancer therapeutic resistance WNT miRNA melanoma melanoma resistance to MAPK/MEK inhibitors resistance to immune checkpoint inhibitors TNBC BRCA1/2 HRR PDL1 TILs PI3KCA PTEN CTCs CSC pancreatic cancer K-RAS oncogene oncogene dependency targeted therapies genomic mutations transcriptomics metabolomics selenoproteins cancer HUB nodes major histocompatibility complex (MHC) human leukocyte antigen (HLA) antigen processing machinery (APM) molecules carcinogenesis tumor predisposition cancer immunotherapy pheochromocytoma paraganglioma head and neck neoplasms head and neck tumors genetic syndromes mutations hyperglycemia cardioncology nivolumab cytokines cardiotoxicity acetyltransferase cancer prognosis NAA10 n/a thema EDItEUR::M Medicine and Nursing New Prognostic and Predictive Markers in Cancer Progression |
| title | New Prognostic and Predictive Markers in Cancer Progression |
| title_full | New Prognostic and Predictive Markers in Cancer Progression |
| title_fullStr | New Prognostic and Predictive Markers in Cancer Progression |
| title_full_unstemmed | New Prognostic and Predictive Markers in Cancer Progression |
| title_short | New Prognostic and Predictive Markers in Cancer Progression |
| title_sort | new prognostic and predictive markers in cancer progression |
| topic | MSI2 OSCC oral cancer musashi 2 prognosis N-cadherin EMT breast cancer new metastasis eribulin blood biomarker bladder cancer immune checkpoint inhibitor CD8+ T effector cells microRNA biomarkers head and neck cancer laryngeal cancer prediction metastasis lifestyle habit chemo-/radio resistance therapeutic target AKT AR castration-resistant prostate cancer (CRPC) MAPK mTOR PI3K prostate cancer therapeutic resistance WNT miRNA melanoma melanoma resistance to MAPK/MEK inhibitors resistance to immune checkpoint inhibitors TNBC BRCA1/2 HRR PDL1 TILs PI3KCA PTEN CTCs CSC pancreatic cancer K-RAS oncogene oncogene dependency targeted therapies genomic mutations transcriptomics metabolomics selenoproteins cancer HUB nodes major histocompatibility complex (MHC) human leukocyte antigen (HLA) antigen processing machinery (APM) molecules carcinogenesis tumor predisposition cancer immunotherapy pheochromocytoma paraganglioma head and neck neoplasms head and neck tumors genetic syndromes mutations hyperglycemia cardioncology nivolumab cytokines cardiotoxicity acetyltransferase cancer prognosis NAA10 n/a thema EDItEUR::M Medicine and Nursing |
| topic_facet | MSI2 OSCC oral cancer musashi 2 prognosis N-cadherin EMT breast cancer new metastasis eribulin blood biomarker bladder cancer immune checkpoint inhibitor CD8+ T effector cells microRNA biomarkers head and neck cancer laryngeal cancer prediction metastasis lifestyle habit chemo-/radio resistance therapeutic target AKT AR castration-resistant prostate cancer (CRPC) MAPK mTOR PI3K prostate cancer therapeutic resistance WNT miRNA melanoma melanoma resistance to MAPK/MEK inhibitors resistance to immune checkpoint inhibitors TNBC BRCA1/2 HRR PDL1 TILs PI3KCA PTEN CTCs CSC pancreatic cancer K-RAS oncogene oncogene dependency targeted therapies genomic mutations transcriptomics metabolomics selenoproteins cancer HUB nodes major histocompatibility complex (MHC) human leukocyte antigen (HLA) antigen processing machinery (APM) molecules carcinogenesis tumor predisposition cancer immunotherapy pheochromocytoma paraganglioma head and neck neoplasms head and neck tumors genetic syndromes mutations hyperglycemia cardioncology nivolumab cytokines cardiotoxicity acetyltransferase cancer prognosis NAA10 n/a thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20210501_9783039439775_119 |